Brian Reichardt, MD
Critical Care Medicine · O Fallon, ILNPI 1689802001
Payments from drug & device makers
Across 1,257 payments — averaging $709.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$481K
- Sanofi$147K
- GSK$142K
- Regeneron Healthcare Solutions, Inc.$45K
- Boehringer Ingelheim$40K
- Grifols USA, LLC$12K
- plus $25K from 22 others
What the payments were for
- Consulting fees$114,31813%
- Speaking & faculty fees$662,43674%
- Travel & lodging$81,9919%
- Food & beverage$28,9463%
- Education$4,1110%
- Gifts$260%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 635 | $481,195 |
| Sanofi | 127 | $147,148 |
| GSK | 225 | $142,217 |
| Regeneron Healthcare Solutions, Inc. | 77 | $45,057 |
| Boehringer Ingelheim | 56 | $39,583 |
| Grifols USA, LLC | 28 | $11,602 |
| Intuitive Surgical | 25 | $7,621 |
| Genentech USA, Inc. | 16 | $5,007 |
| Amgen | 9 | $4,950 |
| Regeneron | 2 | $3,564 |
| Viiv Healthcare Company | 1 | $1,600 |
| Grifols Shared Services North America, Inc. | 3 | $1,159 |
| Insmed, Inc. | 13 | $192 |
| Philips North America LLC | 6 | $146 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $139 |
| Johnson & Johnson(2 entities) | 3 | $124 |
| Shire North American Group Inc | 3 | $105 |
| Sanofi-aventis U.S. LLC | 1 | $86 |
| Verona Pharma, Inc. | 4 | $74 |
| Electromed, Inc. | 6 | $49 |
| Viatris Specialty LLC | 2 | $45 |
| Medtronic | 1 | $42 |
| Resmed Corp | 1 | $30 |
| Sunovion Pharmaceuticals Inc. | 2 | $23 |
| Mylan Specialty L.p. | 1 | $23 |
| Baxter Healthcare | 1 | $21 |
| Galvanize Therapeutics, Inc | 1 | $14 |
| Convatec Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$169,523
- BREZTRI$141,075
- FASENRA$128,762
- AIRSUPRA$100,708
- NUCALA$74,097
- TEZSPIRE$67,419
- TRELEGY ELLIPTA$33,400
- AREXVY$21,359
- Prolastin-C Liquid$12,314
- BREZTRI AEROSPHERE$8,692
- Da Vinci Surgical System$7,151
- OFEV$3,266
How this compares
$891,828 in reported general payments places this provider in the 95th percentile of 281 critical care medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 803 | $666,231 |
| Dupixent PenDupilumab | 109 | $461,188 |
| NucalaMepolizumab | 74 | $308,604 |
| TezspireTezepelumab-Ekko | 59 | $250,627 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 334 | $236,492 |
| OfevNintedanib Esylate | 11 | $223,609 |
| Fasenra PenBenralizumab | 37 | $216,052 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 213 | $130,730 |
| Breo ElliptaFluticasone/Vilanterol | 277 | $118,883 |
| Spiriva HandihalerTiotropium Bromide | 70 | $50,693 |
| Spiriva RespimatTiotropium Bromide | 49 | $40,337 |
| SymbicortBudesonide/Formoterol Fumarate | 103 | $32,365 |
| Incruse ElliptaUmeclidinium Bromide | 78 | $30,964 |
| Advair HfaFluticasone Propion/Salmeterol | 52 | $20,153 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 615 | $17,392 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $142,217 | $1,261,8701,466 claims |
| AstraZenecaTezspire, Breztri Aerosphere, Symbicort, Airsupra | $481,195 | $531,788523 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Combivent Respimat | $39,583 | $273,58474 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 281 critical care medicine providers in Illinois.
Other critical care medicine in O Fallon
- Daniel DillingMaywood$1.2M
- Michael CutticaChicago$765K
- Subramanyam ChittiveluPeoria$215K
- Karen WhiteUrbana$170K
- John RickelmanQuincy$158K
- Raul GazmuriNorth Chicago$158K
- Israel RubinsteinChicago$107K
- Marc SalaChicago$55K
- Abbas Al-QamariChicago$40K
- Sean ForsytheMaywood$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.